Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial tested a drug called prexasertib in people with ovarian cancer. Participants were divided into four groups (called cohorts) based on their cancer type or characteristics. In total, 169 people started the trial — 53 in Cohort 1, 46 in Cohort 2, 41 in Cohort 3, and 29 in Cohort 4. The main thing the trial was measuring was how many participants' tumours shrank or disappeared (known as the "overall response rate"). The trial also tracked how long those responses lasted, how long participants went without their disease getting worse, changes in a blood marker called CA-125, and how the drug moved through the body. The reported data shows that, for the main measure, the percentage of participants whose tumours shrank significantly or disappeared was 11.3% in Cohort 1, 13.0% in Cohort 2, 12.2% in Cohort 3, and 6.9% in Cohort 4. For a broader measure — the percentage of participants whose disease either shrank or stayed stable for at least four months — the reported figures were 45.3% (Cohort 1), 32.6% (Cohort 2), 31.7% (Cohort 3), and 31.0% (Cohort 4). Among those whose tumours did respond, the reported length of time that response lasted ranged from approximately 3.8 months (Cohort 2) to 8.6 months (Cohort 1). The reported time from enrolment until disease worsened or death (progression-free survival) was between roughly 3.6 and 3.9 months across all four cohorts. The percentage of participants who showed at least a 50% drop in the CA-125 blood marker ranged from about 17% (Cohort 3) to approximately 40% (Cohort 1). These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Ovarian Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You are a woman diagnosed with a specific type of ovarian, peritoneal, or fallopian tube cancer called "high-grade serous."
- (Cohorts 1–3) Your cancer has stopped responding to platinum-based chemotherapy, and you have had genetic testing done on your BRCA1 and BRCA2 genes before starting the study treatment.
- (Cohort 1) Your BRCA test came back negative, and you have already received 3 or more different rounds of cancer treatment.
- (Cohort 2) Your BRCA test came back negative, and you have received fewer than 3 prior rounds of cancer treatment.
- (Cohort 3) Your BRCA test came back positive, and you have previously been treated with a type of drug called a PARP inhibitor.
- (Cohort 4) Your cancer did not respond to platinum-based chemotherapy from the very beginning.
- Your liver, kidneys, and other organs are working well enough to safely participate.
- You are willing and able to have a small sample of your tumor removed (biopsy) as required by the study.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- (Cohorts 1–3) You have already received all three of the following chemotherapy drugs during your platinum-resistant treatment: gemcitabine, pegylated liposomal doxorubicin, and paclitaxel.
- Your cancer has spread to your brain or spinal cord.
- You have previously taken part in a study involving a specific type of drug called a "checkpoint kinase 1 inhibitor," or you are known to be allergic to the study drug or its ingredients.
- You have a history of an abnormal opening or tear in your abdomen or digestive tract (fistula or perforation), an infection inside your abdomen in the last 3 months, or a confirmed bowel blockage in the last 3 months.
- You have an active HIV infection that is causing symptoms, or an active hepatitis A, B, or C infection that is causing symptoms.
- You have a serious heart condition.
- You have previously had radiation therapy covering your entire pelvic area.
- You take corticosteroid (steroid) tablets or injections every day on an ongoing basis — steroid inhalers or creams applied to the skin are allowed.
- You have known factors that could raise your risk of infection during the study, such as a drainage tube placed in your abdomen or open wounds (confirm with trial site for full details).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 8 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR): Overall Response Rate (ORR)
Other options
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.